Treatment of Ezetimibe Lowers Total and Low-density Lipoprotein Cholesterol in Hypercholesterolemic Dogs with Hyperadorenocorticism

Overview

Journal J Vet Med Sci

Specialty Veterinary Medicine

Date 2024 Feb 21

PMID 38383002

Authors

Hitomi Oda

Aiko Haga

Kaoru Koyama

Kureha Gokita

Ran Akiyama

Takumi Komiya

Shinogu Hasegawa

Toshinori Sako

Akihiro Mori

Affiliations

Soon will be listed here.

Abstract

Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of both biliary and dietary cholesterol, thereby lowering primarily low density lipoprotein-cholesterol (LDL-chol) in human studies. This study aimed to investigate the effects of ezetimibe on dyslipidemia control in nine dogs with hypercholesterolemia. Changes in total cholesterol (T-chol) and each lipoprotein fractions were evaluated at 0, 2, and 4 months following initiation of ezetimibe treatment. A significant decrease in T-chol was observed, and a mean T-chol concentration below 400 mg/dL was achieved at 2 and 4 months. Furthermore, a significant decrease in LDL-chol was observed (-53.3% and -64.3% at 2 and 4 months, respectively). Taken together, treatment of ezetimibe could lower LDL-chol levels in dogs with hypercholesterolemia.

Citing Articles

Species Differences in Ezetimibe Glucuronidation.

Emmanuel S, Asare E, Du T, Xie H, Liang D, Gao S Metabolites. 2024; 14(11).

PMID: 39590805 PMC: 11597066. DOI: 10.3390/metabo14110569.

References

Oda H, Mori A, Hirowatari Y, Takoura T, Manita D, Takahashi T . Cholesterol concentrations in lipoprotein fractions separated by anion-exchange-high-performance liquid chromatography in healthy dogs and dogs with hypercholesterolemia. Res Vet Sci. 2017; 114:163-169. DOI: 10.1016/j.rvsc.2017.04.004. View

Mori N, Lee P, Muranaka S, Sagara F, Takemitsu H, Nishiyama Y . Predisposition for primary hyperlipidemia in Miniature Schnauzers and Shetland sheepdogs as compared to other canine breeds. Res Vet Sci. 2010; 88(3):394-9. DOI: 10.1016/j.rvsc.2009.12.003. View

Turley S, Dietschy J . Sterol absorption by the small intestine. Curr Opin Lipidol. 2003; 14(3):233-40. DOI: 10.1097/00041433-200306000-00002. View

Hirowatari Y, Yoshida H, Fueki Y, Ito M, Ogura Y, Sakurai N . Measurement of cholesterol concentrations of major serum lipoprotein classes in haemodialysis patients by anion-exchange chromatography. Ann Clin Biochem. 2008; 45(Pt 6):571-4. DOI: 10.1258/acb.2008.008018. View

Telford D, Sutherland B, Edwards J, Andrews J, Barrett P, Huff M . The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res. 2006; 48(3):699-708. DOI: 10.1194/jlr.M600439-JLR200. View

Behrend E, Kooistra H, Nelson R, Reusch C, Scott-Moncrieff J . Diagnosis of spontaneous canine hyperadrenocorticism: 2012 ACVIM consensus statement (small animal). J Vet Intern Med. 2013; 27(6):1292-304. DOI: 10.1111/jvim.12192. View

Rogers W, Donovan E, Kociba G . Lipids and lipoproteins in normal dogs and in dogs with secondary hyperlipoproteinemia. J Am Vet Med Assoc. 1975; 166(11):1092-1100. View

Xenoulis P, Suchodolski J, Levinski M, Steiner J . Investigation of hypertriglyceridemia in healthy Miniature Schnauzers. J Vet Intern Med. 2008; 21(6):1224-30. DOI: 10.1892/07-051.1. View

Kim J, Tsujino T, Fujioka Y, Saito K, Yokoyama M . Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res. 2003; 26(4):307-13. DOI: 10.1291/hypres.26.307. View

10.

Nussbaumer B, Glechner A, Kaminski-Hartenthaler A, Mahlknecht P, Gartlehner G . Ezetimibe-Statin Combination Therapy. Dtsch Arztebl Int. 2016; 113(26):445-53. PMC: 4946327. DOI: 10.3238/arztebl.2016.0445. View

11.

Hess R, Kass P, Van Winkle T . Association between diabetes mellitus, hypothyroidism or hyperadrenocorticism, and atherosclerosis in dogs. J Vet Intern Med. 2003; 17(4):489-94. DOI: 10.1111/j.1939-1676.2003.tb02469.x. View

12.

Lei S, Sun R, Wang D, Gong M, Su X, Yi F . Increased Hepatic Fatty Acids Uptake and Oxidation by LRPPRC-Driven Oxidative Phosphorylation Reduces Blood Lipid Levels. Front Physiol. 2016; 7:270. PMC: 4941416. DOI: 10.3389/fphys.2016.00270. View

13.

Gencer B, Marston N, Im K, Cannon C, Sever P, Keech A . Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020; 396(10263):1637-1643. PMC: 8015314. DOI: 10.1016/S0140-6736(20)32332-1. View

14.

Bissonnette S, Habib R, Sampalis F, Boukas S, Sampalis J . Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On.... Can J Cardiol. 2006; 22(12):1035-44. PMC: 2568964. DOI: 10.1016/s0828-282x(06)70319-1. View

15.

Tenenbaum A, Motro M, Fisman E, Schwammenthal E, Adler Y, Goldenberg I . Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004; 109(18):2197-202. DOI: 10.1161/01.CIR.0000126824.12785.B6. View

16.

Tenenbaum A, Motro M, Fisman E, Adler Y, Shemesh J, Tanne D . Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005; 26(19):2032-8. DOI: 10.1093/eurheartj/ehi310. View

17.

Bays H, Neff D, Tomassini J, Tershakovec A . Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther. 2008; 6(4):447-70. DOI: 10.1586/14779072.6.4.447. View

18.

Xenoulis P, Steiner J . Lipid metabolism and hyperlipidemia in dogs. Vet J. 2009; 183(1):12-21. DOI: 10.1016/j.tvjl.2008.10.011. View

19.

Jonkers I, Mohrschladt M, Westendorp R, van der Laarse A, Smelt A . Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med. 2002; 112(4):275-80. DOI: 10.1016/s0002-9343(01)01123-8. View

20.

Kon M, Hirayama S, Horiuchi Y, Ueno T, Idei M, Fueki Y . Profiles of inflammatory markers and lipoprotein subclasses in patients undergoing continuous ambulatory peritoneal dialysis. Clin Chim Acta. 2010; 411(21-22):1723-7. DOI: 10.1016/j.cca.2010.07.016. View